Marx Wolfgang, McCarthy Alexandra L, Ried Karin, Vitetta Luis, McKavanagh Daniel, Thomson Damien, Sali Avni, Isenring Liz
Centre of Dietetics Research, University of Queensland, St Lucia, Brisbane, QLD, Australia.
BMC Complement Altern Med. 2014 Apr 9;14:134. doi: 10.1186/1472-6882-14-134.
Preliminary research shows ginger may be an effective adjuvant treatment for chemotherapy-induced nausea and vomiting but significant limitations need to be addressed before recommendations for clinical practice can be made.
METHODS/DESIGN: In a double-blinded randomised-controlled trial, chemotherapy-naïve patients will be randomly allocated to receive either 1.2 g of a standardised ginger extract or placebo per day. The study medication will be administrated as an adjuvant treatment to standard anti-emetic therapy and will be divided into four capsules per day, to be consumed approximately every 4 hours (300 mg per capsule administered q.i.d) for five days during the first three cycles of chemotherapy. Acute, delayed, and anticipatory symptoms of nausea and vomiting will be assessed over this time frame using a valid and reliable questionnaire, with nausea symptoms being the primary outcome. Quality of life, nutritional status, adverse effects, patient adherence, cancer-related fatigue, and CINV-specific prognostic factors will also be assessed.
Previous trials in this area have noted limitations. These include the inconsistent use of standardized ginger formulations and valid questionnaires, lack of control for anticipatory nausea and prognostic factors that may influence individual CINV response, and the use of suboptimal dosing regimens. This trial is the first to address these issues by incorporating multiple unique additions to the study design including controlling for CINV-specific prognostic factors by recruiting only chemotherapy-naïve patients, implementing a dosing schedule consistent with the pharmacokinetics of oral ginger supplements, and independently analysing ginger supplements before and after recruitment to ensure potency. Our trial will also be the first to assess the effect of ginger supplementation on cancer-related fatigue and nutritional status. Chemotherapy-induced nausea and vomiting are distressing symptoms experienced by oncology patients; this trial will address the significant limitations within the current literature and in doing so, will investigate the effect of ginger supplementation as an adjuvant treatment in modulating nausea and vomiting symptoms.
ANZCTR.org.au Identifier: ACTRN12613000120774.
初步研究表明,生姜可能是化疗引起的恶心和呕吐的一种有效辅助治疗方法,但在提出临床实践建议之前,需要解决一些重大局限性。
方法/设计:在一项双盲随机对照试验中,未接受过化疗的患者将被随机分配,每天接受1.2克标准化生姜提取物或安慰剂。研究药物将作为标准止吐疗法的辅助治疗,每天分为四粒胶囊,在化疗的前三个周期中,每4小时服用一次(每粒胶囊300毫克,每日四次),持续五天。在此时间段内,将使用有效且可靠的问卷评估恶心和呕吐的急性、延迟和预期症状,恶心症状为主要结果。还将评估生活质量、营养状况、不良反应、患者依从性、癌症相关疲劳以及化疗引起的恶心和呕吐特异性预后因素。
该领域以前的试验指出了一些局限性。这些局限性包括标准化生姜制剂和有效问卷的使用不一致、对预期恶心和可能影响个体化疗引起的恶心和呕吐反应的预后因素缺乏控制,以及使用了次优给药方案。本试验是第一个通过在研究设计中纳入多个独特补充措施来解决这些问题的试验,包括仅招募未接受过化疗的患者来控制化疗引起的恶心和呕吐特异性预后因素、实施与口服生姜补充剂药代动力学一致的给药方案,以及在招募前后独立分析生姜补充剂以确保效力。我们的试验也将是第一个评估生姜补充剂对癌症相关疲劳和营养状况影响的试验。化疗引起的恶心和呕吐是肿瘤患者经历的痛苦症状;本试验将解决当前文献中的重大局限性,并在此过程中研究生姜补充剂作为辅助治疗对调节恶心和呕吐症状的效果。
ANZCTR.org.au标识符:ACTRN12613000120774。